Traws Pharma, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
TRAW$0.23-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, · | |||||||
| · 2025 · 2024 | |||||||
| Operating activities: | | | | | | | |
| Net income (loss) | | $21,490,000 | | $(4,983,000) | | ||
| Adjustment to reconcile net loss to net cash used in operating activities: | | | | | | | |
| Change in fair value of warrant liability | | | (26,513,000) | | | — | |
| Depreciation and amortization | | 1,000 | | 4,000 | | ||
| Stock-based compensation | | 161,000 | | 333,000 | | ||
| Changes in assets and liabilities: | | | | | | | |
| Receivables | | 111,000 | | — | | ||
| Prepaid expenses and other current assets | | 774,000 | | 76,000 | | ||
| Other assets | | | (197,000) | | | — | |
| Accounts payable | | (605,000) | | 949,000 | | ||
| Accrued expenses and other current liabilities | | (602,000) | | (747,000) | | ||
| Deferred revenue | | (57,000) | | (56,000) | | ||
| Net cash used in operating activities | | (5,437,000) | | (4,424,000) | | ||
| | | | | | | | |
| Financing activities: | | | | | | | |
| Proceeds from sale of common stock related to the ATM | | | 122,000 | | | — | |
| Payment of offering costs | | | (123,000) | | | — | |
| Proceeds from exercised prefunded warrants | | | 14,000 | | | — | |
| Net cash provided by financing activities | | 13,000 | | — | | ||
| Effect of foreign currency translation on cash | | 23,000 | | (7,000) | | ||
| Net decrease in cash and cash equivalents | | (5,401,000) | | (4,431,000) | | ||
| Cash and cash equivalents at beginning of period | | 21,338,000 | | 20,821,000 | | ||
| Cash and cash equivalents at end of period | | $15,937,000 | | $16,390,000 | | ||
| Supplemental disclosure of cash flow information: | | | | | | | |
| Deferred offering costs in accounts payable | | $75,000 | | $— | | ||
| Reclassification of warrant liability upon exercise of prefunded warrants and amended warrant agreements | | $15,827,000 | | $— | | ||
Notes to Condensed Consolidated Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.